Last updated on November 2017

A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia (EMPHENE)


Brief description of study

A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia (EMPHENE)

Detailed Study Description

PHN double blind trial

Clinical Study Identifier: TX84876

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jay Dobson

Northwest Clinical Research Center
Bellevue, WA USA
  Connect »